Bayer accepts Kerendia filing: JPMorgan keeps target for Bayer stock at EUR 61.00

Published on 10/09/2026 at 11:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer's Q2 revenue reached EUR 10.87 billion, up 2.20 percent year over year. Bayer stock stood at EUR 43.31 on October 9, 2026, plus 0.60 percent versus EUR 43.05.

Key points in brief

Bayer accepted an expanded Kerendia filing on October 8, 2026, based on Phase III FIND-CKD data.
JPMorgan maintained a EUR 61.00 target and an Overweight rating on October 1, 2026.
Bayer stock traded at EUR 43.31 at Lang & Schwarz on October 9, 2026, plus 0.60 percent versus EUR 43.05.

Pop-Art-Comicpanel: begeisterter Forscher im weißen Kittel hält Reagenzglas triumphierend hoch, große Sprechblase mit DISCOVERY!, gelber Hintergrund mit roten Rasterpunkten, blauer Explosionsstern — Pop-Art-Comic im Lichtenstein-Stil: Forscher im Kittel hält jubilierend Reagenzglas hoch, Sprechblase DISCOVERY!, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 43.31 at Lang & Schwarz on October 9, 2026, plus 0.60 percent versus the prior close of EUR 43.05. Bayer said on October 8, 2026, that the U.S. Food and Drug Administration had accepted its application to expand Kerendia for chronic kidney disease without diabetes, based on Phase III FIND-CKD data. On October 1, 2026, FinanzNachrichten reported that JPMorgan kept its Overweight rating and EUR 61.00 target for Bayer.

Three milestones define the story

On September 23, 2026, Bayer placed hybrid bonds worth EUR 2.00 billion, according to Bayer. On October 2, 2026, the company announced a USD 2.20 billion production site in New Albany, Ohio, with about 600 permanent jobs, according to Bayer. The October 8, 2026, Kerendia filing is the latest milestone and adds a Phase III clinical-data catalyst to the pharmaceuticals portfolio.

What does the US investment change?

The New Albany project puts USD 2.20 billion behind Bayer's US pharmaceutical manufacturing footprint, while the United States already accounts for 35.00 percent of the company's global pharmaceutical sales, according to wallstreetONLINE. That capital commitment matters because it links the company's expansion plan to a market already generating more than one-third of pharmaceutical revenue.

Revenue grows while analysts trim caution

In the second quarter of 2026, Bayer reported revenue of EUR 10.87 billion, up 2.20 percent from the prior-year period, and EBITDA before special items of EUR 2.14 billion, up 1.90 percent, according to Bayer. JPMorgan's EUR 61.00 target stands EUR 17.69 above the Lang & Schwarz price, equal to 40.85 percent upside from the reference price, but the bank said early third-quarter expectations appeared high because of timing effects in agriculture.

Next report arrives in November

Bayer's next quarterly report is scheduled for November 3, 2026, according to FinanzNachrichten. The date gives investors a concrete checkpoint for the 1.30 percent third-quarter revenue-growth expectation and the projected 10.00 percent decline in operating profit versus the prior-year quarter.

Stock holds above the prior close

Bayer stock was trading at EUR 43.31 at Lang & Schwarz on October 9, 2026 at 11:40 a.m. CEST, up 0.60 percent versus the prior close of EUR 43.05 on October 8, 2026. The primary listing is Xetra, where the finance quote showed EUR 43.40 on October 9, 2026; the Lang & Schwarz quote remains the reference for this article. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.